Mizuna Sekine is an associate in the Bay Area offices of Latham & Watkins and a member of Latham’s Corporate Department and Healthcare & Life Sciences Practice.

Ms. Sekine advises private and public companies primarily in the life sciences area in various transactional matters, including licenses, collaborations, technology transfer, mergers, acquisitions, and public offerings.

Ms. Sekine brings clients technical insight coupled with her passion for bringing innovation to market. She regularly advises clients on matters including:

  • Intellectual property and technology licenses
  • Joint ventures and strategic alliances
  • Venture financings, public offerings, M&A, and other strategic transactions 
  • Manufacturing, supply, distribution, and other commercial agreements
  • Research, development, and clinical trial agreements

Ms. Sekine earned a Master of Chemistry degree at Oxford University (Trinity College) for her work in Dr. Colin Bain’s laboratory on chemistry of surfaces and interfaces. She is registered to practice before the United States Patent and Trademark Office (USPTO) and is a Certified Information Privacy Professional in both Europe (CIPP/E) and the United States (CIPP/US).

Ms. Sekine maintains an active pro bono practice, regularly advising non-profit organizations in relation to their regulatory and commercial needs.

Ms. Sekine’s experience includes advising:

  • Coherus BioSciences, a commercial-stage biopharmaceutical company, in its:
    • US$40 million divestment of YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd.
    • US$76.2 million combined term loan and product royalty financing agreement with Barings
  • Verona Pharma, a clinical-stage biopharmaceutical company, in its US$650 million strategic financing with Oaktree and OMERS
  • Pionyr Immunotherapeutics, a clinical-stage biotechnology company, in its acquisition by Ikena Oncology, a targeted oncology company forging new territory in patient-directed cancer treatment
  • CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, in its US$281.3 million initial public offering on the Nasdaq Global Select Market

Bar Qualification

  • California
  • England and Wales (Solicitor)
  • New York
  • US Patent and Trademark Office

Education

  • LL.M., Stanford Law School
  • Diploma, The Legal Training and Research Institute of Japan
  • J.D., Keio University
  • M.Chem in Chemistry, University of Oxford

Languages Spoken

  • English
  • Japanese